Cross-Sectional Survey on BNT162b2 mRNA COVID-19 Vaccine Serious Adverse Events in Children 5 to 11 Years of Age: A Monocentric Experience

Vaccines, Год журнала: 2022, Номер 10(8), С. 1224 - 1224

Опубликована: Июль 30, 2022

Our aim was to evaluate the safety of COVID-19 vaccine in children resident Latina Local Health Authority.We conducted a telephone survey among aged 5-11 years receiving BNT162b2 mRNA between December 15 and 21. The main outcomes included presence allergic reactions or anaphylaxis, adverse events after 24-48 h, 7 20 days taking first second doses medications, documented SARS-CoV-2 infection vaccination. information obtained automatically linked spreadsheet analyzed.569 were enrolled. mean age 114 ± 4.24 months; there 251 males study. showed favorable profile; no anaphylaxis serious reported. most common symptoms both dose injection site reactions, asthenia, headache. Injection more frequent (p = 0.01), while systemic 0.022). These patients with comorbidities 0.0159).Our findings confirm younger 11 could be useful promote its diffusion pediatric ages order achieve "herd immunity" prevent virus's circulation.

Язык: Английский

---

Clinical features, diagnosis, and management of COVID-19 vaccine-associated Vogt-Koyanagi-Harada disease

Human Vaccines & Immunotherapeutics, Год журнала: 2023, Номер 19(2)

Опубликована: Июнь 6, 2023

Vogt-Koyanagi-Harada (VKH) disease is a rare and serious ocular adverse reaction following COVID-19 vaccination. This study aimed to evaluate the clinical features, diagnosis management of vaccine-associated VKH disease. Case reports after vaccination were collected up February 11, 2023 for retrospective analysis. Twenty-one patients (9 males 12 females) included, with median age 45 years (range 19-78), from three main regions, Asia (12/21), Mediterranean region (4/21), South America (5/21). Fourteen developed symptoms first dose vaccine, 8 second dose. Vaccines included mRNA vaccine (10 cases), virus vector (6 inactivated (5 cases). The average time interval onset was 7.5 days hours 4 weeks). All 21 experienced visual impairment vaccination, 20 cases involving both eyes. Sixteen showed meningitis. Serous retinal detachment observed in 16 patients, choroidal thickening 14, aqueous cell 9, subretinal fluid 6. CSF pleocytosis detected 7 skin found 3 patients. received corticosteroid therapy, also immunosuppressive agents. recovered well, mean recovery 2 months. Early early treatment are crucial prognosis vaccine. risk against history should be evaluated clinically.

Язык: Английский

---

Efficacy, Effectiveness, and Safety of COVID-19 Vaccine Compared to Placebo in Preventing COVID-19 Infection among 12-17 Years Old: A Systematic Review

Acta Medica Philippina, Год журнала: 2024, Номер 58(7)

Опубликована: Апрель 30, 2024

Objectives. The World Health Organization recently revised their recommendations and considered healthy children adolescents as low priority group for COVID-19 vaccine. This review comprehensively assessed existing clinical evidence on vaccine in 12-17 years old. Methods. Included this were any type of study that investigated the efficacy, immunogenicity, safety, effectiveness protection against SARS-COV-2 infection Various electronic databases searched up to March 15, 2023. Studies screened, data extracted, risk bias appraised, certainty was judged using GRADE. Review Manager 5.4 used estimate pooled effects. Difference between two groups described mean difference continuous variables relative or odds ratio categorical variables. Results. There six randomized controlled trials 16 studies (8 cohorts 8 case control). Low showed BNT162b2 (Pfizer) effective, immunogenic, safe adolescents. 15 adolescent one immunocompromised patients. It protective with variants, higher Delta than Omicron. is hospitalization emergency urgent care (high certainty); critical MIS-C (low). Very noted BNT 162b2 also immunogenic 12-21 old rheumatic diseases while immunomodulatory treatment but possible increased exacerbation illness. demonstrated mRNA-1273 (Moderna) safe. very safety immunogenicity vector base vaccines (ChAdOx1-19 Ad5 COVID vaccine) inactivated (CoronaVac BBIBP CorV). Conclusion. presently use RNA Therecommendation its weak. insufficient andvector-based vaccines. Different countries should consider whether vaccinate adolescentwithout comprising other recommended immunization health priorities are crucial agegroup. Other factors including cost-effectiveness vaccination disease burden be accounted.

Язык: Английский

---

Clinical features of coronavirus disease 2019 in Korean pediatric patients: a single-center retrospective study

Kosin Medical Journal, Год журнала: 2024, Номер 39(2), С. 99 - 111

Опубликована: Июнь 10, 2024

Background: To address the public’s fear of coronavirus disease 2019 (COVID-19), understanding clinical features is essential. However, research on COVID-19, including illness duration and post-acute in Korean pediatric patients has been limited. Therefore, this study investigated COVID-19 based medical records with a history who visited single center. Methods: In total, 311 were included study. The presence 19 symptoms examined. Additionally, by dividing into different age ranges. Patients aged 6 above further categorized according to asthma, while adolescent divided vaccinated unvaccinated groups.Results: Fever cough most common symptoms. mean was 2–4 days. Only 3.5% asymptomatic. Post-acute observed 13.2% patients. incidence tended increase age. more frequently asthma than those without asthma. Vaccinated experienced less fever, vomiting, fatigue patients.Conclusions: Our data suggest that had mild lasting week, course may differ depending findings also indicate vaccination alleviate breakthrough infections.

Язык: Английский

---

Parental willingness to have children vaccinated against COVID-19 in Geneva, Switzerland: a cross-sectional population-based study

Schweizerische medizinische Wochenschrift, Год журнала: 2023, Номер 153(4), С. 40049 - 40049

Опубликована: Апрель 3, 2023

We aimed to examine factors associated with parental willingness vaccinate their children against COVID-19.We surveyed adults included in a digital longitudinal cohort study composed of participants previous SARS-CoV-2 serosurveys conducted Geneva, Switzerland. In February 2022, an online questionnaire collected information on COVID-19 vaccination acceptance, aged ≥5 years and reasons for preference. used multivariable logistic regression assess the demographic, socioeconomic health-related being vaccinated intention children.We 1,383 (56.8% women; 69.3% 35-49 years). Parental increased markedly child's age: 84.0%, 60.9% 21.2%, respectively, parents adolescents 16-17 years, 12-15 5-12 years. For all child age groups, unvaccinated more frequently indicated not intending than parents. Refusal vaccine was having secondary education (1.73; 1.18-2.47) relative tertiary middle (1.75; 1.18-2.60) low (1.96; 1.20-3.22) household income high income. also only (3.08; 1.61-5.91), 5-11 (19.77; 10.27-38.05), or multiple groups (6.05; 3.22-11.37), years.Willingness but decreased significantly decreasing age. Unvaccinated, socioeconomically disadvantaged those younger were less likely be willing children. These results are important programs developing communication strategies reach vaccine-hesitant both context prevention other diseases future pandemics.

Язык: Английский

---

Vaccine Effectiveness of Two-Dose BNT162b2 Over Time Against COVID-19 Symptomatic Infection and Severe Cases Among Adolescents: Test Negative Design Case Control Studies in Brazil and Scotland

SSRN Electronic Journal, Год журнала: 2022, Номер unknown

Опубликована: Янв. 1, 2022

Background: Little is known about vaccine effectiveness (VE) over time among adolescents, especially against the SARS-CoV-2 B.1.1.529 (Omicron) variant. This study assessed associations between since two-dose vaccination with BNT162b2 and occurrence of symptomatic infection severe COVID-19 adolescents in Brazil Scotland. Methods: We conducted test-negative design aged 12-17 years related symptoms from September 8, 2021, to March 2022, Scotland August 6, 1, 2022. linked records reverse transcription-polymerase chain reaction (RT-PCR) antigen tests national clinical records. estimated adjusted odds ratio VE 95% CI, using logistic regression, across fortnightly periods, for both countries (hospitalisation or death) Brazil. Findings: Among we analysed 447,882 375,385 varied by predominant circulating It was substantially lower during Omicron dominant period (62.8% 78.3 at peak) than Delta (85.8% 90.7 Scotland). started decline 27 days after second dose, reaching 13.9% 31.3% ≥98 period. In Brazil, protection disease remained 80% 98 receiving dose. Interpretation: found waning However, outcomes infected high ≥ dose Consideration booster doses needs be given. Funding: Medical Research Council, Scottish Government, Health Data UK BREATHE Hub, Fiocruz, Fazer o Bem Faz Programme; CNPQ, Wellcome Trust.Declaration Interest: MB-N reports grants bem faz program JBS S.A.. VdAO, VB, MLB, JC are employees a federal public institution, which manufactures Vaxzevria through full technology transfer agreement AstraZeneca. Fiocruz allocates all its manufactured products Ministry health use. SVK Co-Chair Government's Expert Reference Group on Ethnicity member Scientific Advisory Emergencies (SAGE) subgroup Ethnicity. IR Committee Government Republic Croatia co-Editor-in-Chief Journal Global Health.CRS declares funding National Institute Research, Chief Scientist Office New Zealand Business, Innovation Employment Council conduct this studyEthical Approval: de-identified data approved Ethics committee (CONEP) (CAAE registration no. 50199321.9.0000.0040).

Язык: Английский

---

Diagnosis, treatment and prevention of severe acute respiratory syndrome coronavirus 2 infection in children: experts’ consensus statement updated for the Omicron variant

World Journal of Pediatrics, Год журнала: 2023, Номер 20(3), С. 272 - 286

Опубликована: Сен. 7, 2023

Язык: Английский

---

Contribution of SARS-CoV-2 infection preceding COVID-19 mRNA vaccination to generation of cellular and humoral immune responses in children

Frontiers in Immunology, Год журнала: 2023, Номер 14

Опубликована: Дек. 20, 2023

Primary COVID-19 vaccination for children, 5-17 years of age, was offered in the Netherlands at a time when substantial part this population had already experienced SARS-CoV-2 infection. While has been shown effective, underlying immune responses have not extensively studied. We studied responsiveness to one and/or two doses primary BNT162b2 mRNA and compared humoral cellular response children with without preceding Antibodies targeting original Spike or Omicron were measured by multiplex immunoassay. B-cell T-cell investigated using enzyme-linked immunosorbent spot (ELISpot) assays. The activation CD4 + CD8 T cells flowcytometry. induced both adaptive naive children. These stronger those history infection prior vaccination. A second vaccine dose did further boost antibody levels who previously an Infection-induced mainly detected cells, while vaccine-induced mostly cells. Thus, enhances As most are now expected contract before age five, impact infection-induced immunity is high relevance. Therefore, considering natural as priming immunogen that subsequent vaccine-responsiveness may help decision-making on number timing doses.

Язык: Английский

---

A qualitative exploration of children’s willingness to take the COVID-19 vaccine in Jordan

Journal of Applied Pharmaceutical Science, Год журнала: 2023, Номер unknown

Опубликована: Янв. 1, 2023

Caregivers' adherence to carbamazepine treatmentfor children and adolescents suffering from mentalhealth disordersHebe Karina de Oliveira Stucchi, Marli Gerenutti

Язык: Английский

---

The attitude and knowledge of pediatricians and family physicians toward COVID-19 vaccination in children: A cross-sectional study

Human Vaccines & Immunotherapeutics, Год журнала: 2023, Номер 19(2)

Опубликована: Июль 3, 2023

COVID-19 vaccines to children are expected reduce the transmission of disease high-risk groups and achieve herd immunity in younger populations. A positive attitude toward vaccination among healthcare workers (HCWs) is predicted parents' hesitancy vaccinate their children. This study aimed assess knowledge pediatricians family physicians total 112 96 (specialists residents) were interviewed level knowledge, attitude, perceived safety for Physicians willing receive regular (analogous influenza vaccine) had significantly higher scores (P < .05). Multivariate analysis indicated that a score having at least five years experience as specialist associated with or Pfizer/BioNTech was preferred vaccine both (>67%). Around 71% believed do not cause worsen any health condition. Educational training programs increase about recommended inform more attitude.

Язык: Английский

---